Related Experiment Videos
Hyperlipidemia in Chronic Cholestatic Liver Disease
Matteo Longo1, Andrea Crosignani, Mauro Podda
1Division of Internal Medicine, Department of Medicine, Surgery, and Dentistry, San Paolo School of Medicine, University of Milan, Via di Rudini, 8, Milano 20142, Italy. mauro.podda@unimi.it
Insights
Patients with chronic cholestatic liver disease often have abnormal cholesterol levels. Certain patients may require specific treatments beyond ursodeoxycholic acid to manage cardiovascular risk.
Area of Science:
- Hepatology
- Cardiology
- Endocrinology
Background:
- Hyperlipidemia, particularly elevated low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, is common in chronic cholestatic liver diseases.
- Cardiovascular disease morbidity and mortality are not typically increased, possibly due to cardioprotective elevated HDL levels.
- A subset of patients exhibits high LDL with normal/low HDL, suggesting combined familial/nutritional hypercholesterolemia.
Purpose of the Study:
- To evaluate the lipid profiles in patients with chronic cholestatic liver diseases.
- To assess the cardiovascular risk in these patients.
- To determine appropriate management strategies for hyperlipidemia in this population.
Main Methods:
- Analysis of lipid profiles (LDL, HDL cholesterol) in patients with chronic cholestatic liver diseases.
- Review of existing literature on cardiovascular outcomes and treatment efficacy.
- Evaluation of the impact of ursodeoxycholic acid, cholestyramine, and HMG CoA reductase inhibitors.
Main Results:
- Chronic cholestasis is associated with distinct lipoprotein patterns, often with elevated HDL.
- Some patients present with high LDL and low HDL, indicating increased cardiovascular risk.
- Ursodeoxycholic acid shows limited LDL-lowering capacity, potentially insufficient for high-risk patients.
Conclusions:
- Patients with chronic cholestatic liver disease and high LDL/low HDL require tailored management.
- Dietary changes, weight loss, and specific lipid-lowering drugs may be beneficial.
- Cholestyramine and HMG CoA reductase inhibitors (statins) have roles in managing hyperlipidemia and pruritus in specific patient subgroups.
Abstract:
Hyperlipidemia with a marked increase of low-density lipoprotein (LDL) and high- density lipoprotein (HDL) cholesterol levels is a common feature in patients with chronic cholestatic liver disease. Excess morbidity and mortality from cardiovascular disease has not been reported in these patients. This may be due to the particular lipoprotein pattern observed during chronic cholestasis, characterized by elevated serum HDL cholesterol, which may have a cardioprotective effect. However, in a subgroup of patients with chronic cholestasis, hyperlipidemia is characterized by markedly elevated LDL levels with normal or low HDL levels, probably reflecting hypercholesterolemia with coexisting familial and nutritional origins. Ursodeoxycholic acid, the only drug approved for the treatment of chronic cholestatic liver diseases, has been shown to slightly decrease serum cholesterol concentrations. However, the extent of LDL reduction by ursodeoxycholic acid may be insufficient to protect this subgroup of patients from increased cardiovascular risk. Patients in this subgroup probably would benefit from dietary modification, weight loss, and the administration of specific lipid-lowering drugs. Cholestyramine, which is the first-line treatment for pruritus in chronic cholestasis, may be also indicated for its cholesterol-lowering capacity in patients with hypercholesterolemia who complain of pruritus. Administration of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (simvastatin or pravastatin, 20 mg/d) should be limited to hypercholesterolemic patients with mild chronic cholestatic liver diseases in whom HDL serum levels are below the protective range or if additional risk factors for cardiovascular diseases are present.